Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models

Despite decades of research, there is no specific therapy for acute pancreatitis (AP). In the current study, we have evaluated the efficacy of pirfenidone, an antiinflammatory and antifibrotic agent that is approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF), in ameliorating loc...

Descripción completa

Detalles Bibliográficos
Autores principales: Palathingal Bava, Ejas, George, John, Tarique, Mohammad, Iyer, Srikanth, Sahay, Preeti, Gomez Aguilar, Beatriz, Edwards, Dujon B., Giri, Bhuwan, Sethi, Vrishketan, Jain, Tejeshwar, Sharma, Prateek, Vaish, Utpreksha, C. Jacob, Harrys K., Ferrantella, Anthony, Maynard, Craig L., Saluja, Ashok K., Dawra, Rajinder K., Dudeja, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855813/
https://www.ncbi.nlm.nih.gov/pubmed/34847076
http://dx.doi.org/10.1172/jci.insight.141108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855813/
https://www.ncbi.nlm.nih.gov/pubmed/34847076
http://dx.doi.org/10.1172/jci.insight.141108

Ejemplares similares